SGLT2 vs GLP-1: Mortality Impact in Diabetic CVD Patients
Okay, here’s a breakdown of the references you provided, formatted for better readability.I’ve extracted the key facts from each citation.Note that there are some typos in the original text (e.g., “Slut” instead of “Infarct”), which I’ve corrected in the output.
Reference List
- Liu T, Fan Z, Li Y, Xiao B, He C. Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: a propensity score-matched cohort study. Int J Cardiol. 2025;431:133229.
- Marfella R, Prattichizzo F, Sardu C, Rambaldi PF, Fumagalli C, Marfella LV, La Grotta R, Frigé C, pellegrini V, D’Andrea D, Cesaro A, Calabrò P, Pizzi C, Antonicelli R, Ceriello A, mauro C, Paolisso G. GLP-1 Receptor Agonists-Sglt-2 Inhibitors Combination Therapy And Cardiovascular events After Acute Myocardial Infarction: An Observational Study in Patients With Type 2 Diabetes. Cardiovasc Diabetol. 2024; 23: 10.
CAS Link: https://cardiab.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXmslKhsA%3D%3D
- Chaiyakunapruk N, Tan CX, Liang CY, Guevarra M, Xie CL, Cheng AY. (Citation incomplete – only the author and journal information is provided).
Cardiovasc Diabetol. 2025; 24.
* Google Scholar Link: [http://scholargooglecom/scholar[http://scholargooglecom/scholar[http://scholargooglecom/scholar[http://scholargooglecom/scholarlookup?&journal=Cardiovasc%20Diabetol&volume=24&publicationyear=2025&author=Chaiyakunapruk%2CN&author=Tan%2CX&author=Liang%2CY&author=Guevarra%2CM&author=Xie%2CL&author=Cheng%